Mumbai (Maharashtra) [India], October 16: Lord’s Mark Biotech, a subsidiary of Lord’s Mark Industries and a leading healthcare and wellness company, has launched Tinefcon, a patented medicine developed for treating Psoriasis and Rudojoint, India’s joint cartilage regenerator, a medicine to treat cartilage-related joint disorders like osteoarthritis, articular cartilage injuries as well as sports injuries. Lord’s Mark Biotech has received approval from the Drug Controller General of India (DCGI) and Food Safety and Standards Authority of India (FSSAI) to roll out Tinefcon as a tablet, cream, shower gel and scalp wash, whereas Rudojoint has been introduced as an oral tablet after receiving necessary certification from FDA and GMP.
Lord’s Mark Biotech has signed an exclusivity agreement with INVEX Health Pvt Ltd for a patented product developed by Piramal Life Sciences in India to distribute Tinefcon. Lord’s Mark Biotech, the exclusive distribution partner for tinefcon, is mentoring mentors around the country through a scientific sales force exclusively recruited for Tinefcon to deliver a solution for Psoriasis. The company has also established a strong social media campaign to aggressively market Tinefcon online. Tinefcon will also be offered on internet marketplaces, allowing the medical community to reliably recommend it to needy patients.
Rudojoint contains a patented source of Undenatured Type II Collagen, UC II, wherein both the ingredient and method of manufacturing are patented. As many as 11 human clinical studies have proven the effectiveness of Rudojoint over competitive molecules. Rudojoint has a unique mode of action and is clinically proven to significantly improve joint flexibility 15 times better than placebo.
Commenting on the launch, Mr. Sachidanand Upadhyay, MD, Lord’s Mark Biotech, said, “We are pleased to introduce Tinefcon and Rudojoint to the Indian market. The launch of these two medicines is in line with our mission to enrich the healthcare discourse in India. With Tinefcon, we offer comprehensive, safe and effective treatment of Psoriasis. Our goal is to position Tinefcon as the principal choice for psoriasis management. On the other hand, demand for Rudojoint is set to grow as osteoarthritis cases are set to rise to 60 million in India by 2025 due to growing longevity, obesity, lack of exercise and sometimes work-out-related injuries. We are collaborating with all key stakeholders in the healthcare ecosystem to build a robust distribution network for the medicines.”
Lord’s Mark Biotech has also launched Taspro Mom Protein Powder, a high-quality protein supplement with 29 vital nutrients which contains whey and soy protein to attend to the needs of the mother and the unborn child. It provides high protein to bridge the protein gap, EPA and DHA for foetal brain development, and nutrients for physical development. An unborn child’s sole source of nutrition comes from the mother’s body. This protein powder provides the missing nutrients in the mother’s diet to ensure the optimum health and development of the child.
